Subject ID,Trial ID,Site ID,Report Date,Collection Date,Gender,Disease,Panel,Sensitivity (from Report),Specificity (from Report),Methodology,Nucleic Acid,Library Prep,Platform,Tumor Fraction (%),LOH,Microsatellite Instability Status,Tumor Mutational Burden (Muts/Mb),Gene with co-occurring result,Transcript ID,cDNA Change,Amino Acid Change,Build,Chromosome,Location,Variant type,Clinical significance,Allele Fraction (%),Copy Number,Gene Expression Qualitative,dbSNP ID,COSMIC ID,Depth at Variant,Genotype,Zygosity,Type of Region Analyzed,IHC-PDL1_Antibody ,PDL1 Results
000-111,LY-1234,000,01Feb2021,22Dec2020,Female,Thyroid Gland Medullary Carcinoma,Omniseq Insight,N/A,N/A,NGS,DNA,Hybrid capture-selected libraries are sequenced to high uniform depth (targeting >150X median coverage with >90% of exons at coverage >50X) and the sequnence data is analyzed to detect genomci variants and signatures.,N/A,30,N/A,MS-Stable,4.3,RB1,NM_000321.2,c.13del,T5PfsX60,N/A,N/A,exon1,Deletion-Frameshift,N/A,90,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
000-111,LY-1234,000,01Feb2021,22Dec2020,Female,Thyroid Gland Medullary Carcinoma,Omniseq Insight,N/A,N/A,NGS,DNA,Hybrid capture-selected libraries are sequenced to high uniform depth (targeting >150X median coverage with >90% of exons at coverage >50X) and the sequnence data is analyzed to detect genomci variants and signatures.,N/A,30,N/A,MS-Stable,4.3,RET,NM_020975.4,c.2753T>C,M918T,N/A,N/A,exon16,Substitution-Missense,Pathogenic,34,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
000-111,LY-1234,000,01Feb2021,22Dec2020,Female,Thyroid Gland Medullary Carcinoma,Omniseq Insight,N/A,N/A,NGS,DNA,Hybrid capture-selected libraries are sequenced to high uniform depth (targeting >150X median coverage with >90% of exons at coverage >50X) and the sequnence data is analyzed to detect genomci variants and signatures.,N/A,30,N/A,MS-Stable,4.3,NPM1,N/A,N/A,A190V,N/A,N/A,N/A,Variants of Unknown Significance(VUS),N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
000-111,LY-1234,000,01Feb2021,22Dec2020,Female,Thyroid Gland Medullary Carcinoma,Omniseq Insight,N/A,N/A,NGS,RNA,Hybrid capture-selected libraries are sequenced to high uniform depth (targeting >150X median coverage with >90% of exons at coverage >50X) and the sequnence data is analyzed to detect genomci variants and signatures.,N/A,30,N/A,MS-Stable,4.3,CD27,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A
000-111,LY-1234,000,01Feb2021,22Dec2020,Female,Thyroid Gland Medullary Carcinoma,Omniseq Insight,N/A,N/A,IHC,N/A,N/A,N/A,30,N/A,MS-Stable,4.3,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,N/A,PDL1 IHC (22C3),< 1% Tumor proportion score (Negative)
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
